Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical Officer. This strategic hire comes as Synendos advances its lead asset SYT-510 into Phase 2 clinical development.
”"It’s tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.”
Andrea ChiccaCo-founder and CEO at Synendos Therapeutics
Dr. Garibaldi is a psychiatrist and neuroscientist with more than three decades of experience in global clinical development programs for CNS disorders. He has held senior leadership roles at Roche, Novartis, and Janssen, contributing to the development of innovative treatments including Ocrevus® for primary progressive multiple sclerosis and several investigational agents for Alzheimer’s disease, depression, and PTSD.
As co-founder of Neurama Pharma, Dr. Garibaldi spearheaded the in-licensing and advancement of novel CNS assets, and has published over 100 peer-reviewed articles. He is a fellow and past president of the International Society for CNS Clinical Trials and Methodology, recognized for his collaborative, strategy-led approach to addressing unmet mental health needs.
”Mental health and brain health have for too long been underserved by traditional drug development. Synendos’ mission to innovate around the endocannabinoid system represents a bold and forward-thinking approach. I’m excited to join a team committed to meaningful change for patients worldwide.
Dr. George GaribaldiChief Medical Officer at Synendos Therapeutics
About Synendos
Synendos is a clinical-stage neuroscience company dedicated to developing potentially breakthrough therapies for neuropsychiatric and other CNS disorders such as anxiety, depression, PTSD, and others. The company’s work targets the endocannabinoid system (ECS) through selective endocannabinoid re-uptake inhibitors (SERIs), a first-in-class mechanism of action. Synendos aims to restore the natural functioning of the brain, addressing the urgent need for more effective and better-tolerated treatments.
We welcome Dr. Garibaldi to Synendos and look forward to the impact of his leadership as we enter the next phase of development for SYT-510.
Read the whole press release here.
